Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis

EGFR pathway inhibition may promote anti-programmed cell death protein 1 (PD-1) responses in preclinical models, but how EGFR inhibition affects tumor antigen presentation during anti-PD-1 monotherapy in humans remain unknown. We hypothesized that afatinib, an irreversible EGFR tyrosine kinase inhib...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2022-04, Vol.28 (8), p.1560-1571
Hauptverfasser:	Kao, Hsiang-Fong, Liao, Bin-Chi, Huang, Yen-Lin, Huang, Huai-Cheng, Chen, Chun-Nan, Chen, Tseng-Cheng, Hong, Yuan-Jing, Chan, Ching-Yi, Chia, Jean-San, Hong, Ruey-Long
Format:	Artikel
Sprache:	eng
Schlagworte:	Afatinib - therapeutic use Antibodies, Monoclonal, Humanized Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - genetics Clinical Trials: Targeted Therapy ErbB Receptors - genetics Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - genetics Humans Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - pathology Squamous Cell Carcinoma of Head and Neck - drug therapy Squamous Cell Carcinoma of Head and Neck - genetics Tumor Microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!